Actuate raises $22M to expand GSK-3β cancer trial

Actuate Therapeutics has raised $21.7 million to take its lead oncology asset deeper into the clinic. The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta (GSK-3β) 9-ING-41.